← Back to Search

Janus Kinase Inhibitor

AZD4205 for PTCL

Phase 2
Waitlist Available
Led By Won Seog Kim, PhD
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Does the disease “peripheral T-cell lymphoma” get worse or re-appear after or during the anti-lymphoma treatment?
How many anti-lymphoma therapies have you ever received, except bone marrow transplantation and radiation treatment?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial is to see if a new drug is safe and effective in treating patients with a specific type of cancer who have not responded to other treatments.

Eligible Conditions
  • Relapsed or Refractory Peripheral T Cell Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have peripheral T-cell lymphoma that may not respond well to anti-lymphoma treatment or may come back after treatment.
Select...
You cannot have had too many treatments for lymphoma before, except for bone marrow transplant or radiation therapy.
Select...
You have a medical condition called "peripheral T-cell lymphoma" that has been diagnosed by a doctor.
Select...
What treatments have you received before? Check all that apply.
Select...
This is not an exclusion criterion, it is a prompt for the participant to select any relevant medical conditions they may have.
Select...
Are you willing to take part in a research study, follow its rules, and go to the hospital for check-ups as needed?

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Secondary outcome measures
Area under the plasma concentration versus time curve (AUC) of AZD4205
Incidence of adverse events
Peak Plasma Concentration (Cmax) of AZD4205

Trial Design

4Treatment groups
Experimental Treatment
Group I: AZD4205 Group DExperimental Treatment1 Intervention
Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
Group II: AZD4205 Group CExperimental Treatment1 Intervention
Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
Group III: AZD4205 Group BExperimental Treatment1 Intervention
Group B: Open label AZD4205 at dose B, once daily (Phase 1)
Group IV: AZD4205 Group AExperimental Treatment1 Intervention
Group A: Open label AZD4205 at dose A, once daily (Phase 1)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD4205
2018
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

Dizal PharmaceuticalsLead Sponsor
20 Previous Clinical Trials
1,889 Total Patients Enrolled
Won Seog Kim, PhDPrincipal InvestigatorSamsung Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

AZD4205 (Janus Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04105010 — Phase 2
Peripheral T-Cell Lymphoma Research Study Groups: AZD4205 Group A, AZD4205 Group B, AZD4205 Group C, AZD4205 Group D
Peripheral T-Cell Lymphoma Clinical Trial 2023: AZD4205 Highlights & Side Effects. Trial Name: NCT04105010 — Phase 2
AZD4205 (Janus Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04105010 — Phase 2
Peripheral T-Cell Lymphoma Patient Testimony for trial: Trial Name: NCT04105010 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many medical centers in the US are actively conducting this research project?

"This trial has 5 operational centers, such as Winship Cancer Institute of Emory University in Atlanta, The University of Texas MD Anderson Cancer Center in Houston and Yale Cancer Centre in New Haven. Additionally there are two other sites where the study is taking place."

Answered by AI

What is the current maximum capacity for participants in this research endeavor?

"A total of 160 participants meeting pre-determined eligibility requirements are required for this study. The Winship Cancer Institute of Emory University in Atlanta and the MD Anderson Centre at UT Houston have been identified as trial sites."

Answered by AI

Are there still vacancies for this research endeavor?

"Confirmed. Clinicaltrials.gov states that this medical study is actively recruiting patients, with the initial post dating back to September 10th 2019 and last update occurring on August 25th 2022."

Answered by AI

To what degree is AZD4205 hazardous to people's health?

"There is an adequate amount of evidence to suggest that AZD4205 is safe, thus it was given a score of 2. This being said, no clinical data exists in support of the drug's effectiveness."

Answered by AI

Who else is applying?

What state do they live in?
Georgia
Missouri
Texas
What site did they apply to?
Washington University School of Medicine
The University of Texas MD Anderson Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
2
0

Why did patients apply to this trial?

I just want to help. Just to see if I am diagnosed. Hydrocodone vs 10-325 Lyrica 300mg.
PatientReceived 1 prior treatment
Pay it forward in the name of Science/ Humanity.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

How responsive is this trial?

Most responsive sites:
  1. The University of Texas MD Anderson Cancer Center: < 48 hours
Typically responds via
Phone Call
Average response time
  • < 2 Days
~29 spots leftby Mar 2025